Earlier cardiovascular outcome trials (CVOT) on sodium–glucose cotransporter 2 (SGLT2) inhibitors showed they markedly reduced the risk of hospitalization for HF (HHF) and mortality in patients with T2D and established atherosclerotic cardiovascular diseases (ASCVD) or at high-risk of cardiovascular events [8–10]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.